Guidance is provided in a European setting on the assessment and treatment of postmenopausal
women with or at risk from osteoporosis. Introduction The European Foundation for …

Background: Total hip and total knee arthroplasties are well accepted as reliable and suitable
surgical procedures to return patients to function. Health-related quality-of-life instruments …

It is estimated that over 200 million people worldwide have osteoporosis. The prevalence of
osteoporosis is continuing to escalate with the increasingly elderly population. The major …

Background Once-daily injections of parathyroid hormone or its amino-terminal fragments
increase bone formation and bone mass without causing hypercalcemia, but their effects on …

Background Osteoporotic structural damage and bone fragility result from reduced bone
formation and increased bone resorption. In a phase 2 clinical trial, strontium ranelate, an orally …

Background Risedronate increases bone mineral density in elderly women, but whether it
prevents hip fracture is not known. Methods We studied 5445 women 70 to 79 years old who …

Background: Strontium ranelate, a new oral drug shown to reduce vertebral fracture risk in
postmenopausal women with osteoporosis, was studied in the Treatment of Peripheral …

Background Treatment of osteoarthritis is usually limited to short-term symptom control. We
assessed the effects of the specific drug glucosamine sulphate on the long-term progression …

The purpose of this randomized, double-masked, placebo-controlled study was to
determine the efficacy and safety of risedronate in the prevention of vertebral fractures in …

Guidance is provided in a European setting on the assessment and treatment of
postmenopausal women at risk of fractures due to osteoporosis.